Apilimod
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Apilimod
- Accession Number
- DB05611
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Apilimod (DB05611)
- Weight
- Average: 418.501
Monoisotopic: 418.211724101 - Chemical Formula
- C23H26N6O2
- Synonyms
- Not Available
- External IDs
- STA 5326
- STA-5326
Pharmacology
- Indication
Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- GFW2K84S4L
- CAS number
- 541550-19-0
- InChI Key
- HSKAZIJJKRAJAV-KOEQRZSOSA-N
- InChI
- InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
- IUPAC Name
- 4-{6-[(E)-2-[(3-methylphenyl)methylidene]hydrazin-1-yl]-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl}morpholine
- SMILES
- CC1=CC=CC(\C=N\NC2=CC(=NC(OCCC3=CC=CC=N3)=N2)N2CCOCC2)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 8348782
- ZINC
- ZINC000011726230
- Wikipedia
- Apilimod
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Crohn's Disease (CD) 1 1 Completed Treatment Common Variable Immunodeficiency 1 1, 2 Completed Treatment Crohn's Disease (CD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0278 mg/mL ALOGPS logP 3.91 ALOGPS logP 4.82 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 14.42 ChemAxon pKa (Strongest Basic) 5.89 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 84.76 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 123.26 m3·mol-1 ChemAxon Polarizability 45.92 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on November 18, 2007 11:26 / Updated on June 12, 2020 10:52